编辑|于靖
6月23日,中国生物制药发布公告,拟以总价1.61亿美元(约10.8亿人民币)或每股7.12美元的价格,收购在美国Nasdaq上市的F-star Therapeutics(以下简称F-star)。这一消息立刻在业内引起轰动,F-star股价也应声大涨,当日涨幅近60%,每股报收6.36美元(图1)。
查看全文
chuminhua2020-07-31 00:13
7/29,F-star Therapeutics将与Spring Bank Pharmaceuticals$Spring Bank制药(SBPH)$ 合并,以在纳斯达克上市,支持其双特异性抗体产品线的开发。 几个月前Spring Bank的乙肝2b期试验失败,股价暴跌,该公司转而开发STING激动剂SB 11285。F-star因与大药企开展交易而闻名,最近几年已经聚焦于内部...查看全文
chuminhua2020-01-30 22:54
1/29,Spring Bank Pharmaceuticals$Spring Bank制药(SBPH)$ 的情况越来越糟。该公司研究人员称,一名患者在inarigivir治疗乙肝的IIb期研究中死亡后,他们正在将工作重点转移到STING上面。inarigivir的安全性问题在于潜在的肝细胞功能障碍,和ALT升高。研究失败导致该公司股价暴跌。查看全文
$Spring Bank制药(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-038875 Size: 5 KB 网页链接
$Spring Bank制药(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-038876 Size: 5 KB 网页链接
$Spring Bank制药(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-038877 Size: 5 KB 网页链接
$Spring Bank制药(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-038878 Size: 5 KB 网页链接
$Spring Bank制药(SBPH)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-038879 Size: 5 KB 网页链接
$Spring Bank制药(SBPH)$ 8-K Current report, items 5.07 and 9.01 Accession Number: 0001564590-20-030597 Act: 34 Size: 140 KB 网页链接
$Spring Bank制药(SBPH)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001564590-20-022813 Act: 34 Size: 7 MB 网页链接
$Spring Bank制药(SBPH)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001564590-20-019714 Act: 34 Size: 189 KB 网页链接
$Spring Bank制药(SBPH)$ DEF 14A Other definitive proxy statements Accession Number: 0001564590-20-019685 Act: 34 Size: 1 MB 网页链接
$Spring Bank制药(SBPH)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-20-025591 Size: 11 KB 网页链接